Trials / Not Yet Recruiting
Not Yet RecruitingNCT06649656
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2252 injection | TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle. |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2026-11-01
- Completion
- 2026-12-01
- First posted
- 2024-10-21
- Last updated
- 2024-10-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06649656. Inclusion in this directory is not an endorsement.